Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 9:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 447 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: IV Fluids Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Fructose Intestinal Gluconeogenesis

NCT07209202
View directory record Official record
Conditions
Healthy Participants, Obese But Otherwise Healthy Participants
Interventions
High fructose meal, Low fructose meal, 13C labeled fructose, oral, 13C labeled fructose, intravenous
Other
Lead sponsor
Touro University, California
Other
Eligibility
20 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Vallejo, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 20, 2026, 9:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Phase 2, Open Label, Pharmacokinetic (PK) Study of TLC599 in Subjects With Osteoarthritis of the Knee

NCT03754049
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
TLC599, DSP
Drug
Lead sponsor
Taiwan Liposome Company
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
7
States / cities
Phoenix, Arizona • Miami, Florida • Charleston, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 20, 2026, 9:50 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)

NCT04547140
View directory record Official record
Conditions
COVID-19
Interventions
Liquid Alpha1-Proteinase Inhibitor (Human), Placebo, Standard Medical Treatment
Biological · Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 20, 2026, 9:50 AM EDT
Terminated Phase 2 Interventional Results available

Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis

NCT04438382
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Steroid-Refractory Pneumonitis
Interventions
Infliximab, Intravenous Immunoglobulin Therapy, Prednisone, Methylprednisolone
Biological · Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
18
States / cities
Chicago, Illinois • Baltimore, Maryland • Battle Creek, Michigan + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 20, 2026, 9:50 AM EDT
Recruiting Phase 1Phase 2 Interventional

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

NCT07468136
View directory record Official record
Conditions
Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Diffuse Astrocytoma, Glioblastoma, IDH-Wildtype, Malignant Glioma
Interventions
Biospecimen Collection, Eflornithine, Lumbar Puncture, Magnetic Resonance Imaging, Retifanlimab, Tumor Resection
Procedure · Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 20, 2026, 9:50 AM EDT
Completed Phase 4 Interventional Results available

Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients

NCT01427907
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Calcium acetate oral solution (COS), Sevelamer carbonate
Drug
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
New Haven, Connecticut • North Haven, Connecticut • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 20, 2026, 9:50 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Optimizing PTCy Dose and Timing

NCT03983850
View directory record Official record
Conditions
Graft Versus Host Disease, Hematologic Neoplasms
Interventions
Busulfan, Fludarabine, Cyclophosphamide, Mycophenolate Mofetil, Sirolimus
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 20, 2026, 9:50 AM EDT
Terminated Phase 2 Interventional Results available

Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

NCT01390584
View directory record Official record
Conditions
Lymphoma
Interventions
Doxorubicin, Bleomycin, Vinblastine, PET, INRT, Dacarbazine, Etoposide, Cyclophosphamide, Vincristine, Procarbazine, Prednisone
Drug · Diagnostic Test · Radiation
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Stanford, California • Reading, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 20, 2026, 9:50 AM EDT
Active, not recruiting Not applicable Interventional

Monitoring for Cancer Spread to the Central Nervous System (CNS) in People With Breast Cancer

NCT05130840
View directory record Official record
Conditions
Breast Cancer
Interventions
MRI, Lumbar puncture
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 20, 2026, 9:50 AM EDT
Terminated Phase 3 Interventional

A Study With Imlifidase in Anti-GBM Disease

NCT05679401
View directory record Official record
Conditions
Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
Interventions
Imlifidase, Plasma exchange (PLEX), Cyclophosphamide (CYC), Glucocorticoids
Drug · Procedure
Lead sponsor
Hansa Biopharma AB
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 20, 2026, 9:50 AM EDT
Completed Not applicable Interventional Results available

Effectiveness of Subcutaneous Glargine On The Time To Closure of The Anion Gap in Patients Presenting to the Emergency Department With Diabetic Keto-acidosis

NCT02006342
View directory record Official record
Conditions
Diabetic Ketoacidosis
Interventions
Insulin Glargine, Regular Insulin
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 20, 2026, 9:50 AM EDT
Terminated Not applicable Interventional Results available

Emergency Department (ED) Flow-directed Fluid Optimization Resuscitation Trial (EFFORT)

NCT01128413
View directory record Official record
Conditions
Shock
Interventions
Cheetah NICOM® PLRT, USCOM ® (Ultrasound Cardiac Output Monitor), Inferior Vena Cava (IVC) Ultrasound Collapsibility, CURVES Questionnaire, Lactate Clearance, 500ml Normal Saline Bolus, Clinician Discretion Intravenous Fluid Management
Device · Behavioral · Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 1, 2016 · Synced Oct 20, 2026, 9:50 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab

NCT02747043
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
ABP 798, Rituximab
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Encinitas, California • Mount Sterling, Kentucky • Billings, Montana + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2022 · Synced Oct 20, 2026, 9:50 AM EDT
Terminated Phase 3 Interventional

A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease

NCT05348915
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
Interventions
Inclacumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
18
States / cities
Mobile, Alabama • Little Rock, Arkansas • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 20, 2026, 9:50 AM EDT
Completed Not applicable Interventional Results available

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS)

NCT05174312
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Reprieve Decongestion Management System, Diuretic
Device · Drug
Lead sponsor
Reprieve Cardiovascular, Inc
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
16
States / cities
Fairhope, Alabama • Irvine, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 20, 2026, 9:50 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Furosemide Use to Fill the Bladder of Pediatric Females Awaiting Pelvic Ultrasound

NCT05098366
View directory record Official record
Conditions
Ovarian Torsion
Interventions
Furosemide, Normal saline
Drug
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
8 Years to 18 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 20, 2026, 9:50 AM EDT
Completed Not applicable Interventional Results available

A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease

NCT00350545
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Rituximab, Prednisone, Cyclosporine A, tacrolimus
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Year to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 20, 2026, 9:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Role of Hydration on Exercise Performance - ODIN

NCT02980939
View directory record Official record
Conditions
Dehydration
Interventions
iv fluid infusion
Other
Lead sponsor
University of Arkansas, Fayetteville
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 20, 2026, 9:50 AM EDT
Completed Not applicable Interventional

Restrictive Intravenous Fluids Trial in Sepsis

NCT03137446
View directory record Official record
Conditions
Septic Shock, Severe Sepsis
Interventions
Intravenous Fluid Cap
Other
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 20, 2026, 9:50 AM EDT
Completed No phase listed Observational Results available

T-wave Alternans and Intrathoracic Impedance Measurements

NCT00669682
View directory record Official record
Conditions
Congestive Heart Failure, Arrhythmias
Interventions
Congestive heart failure
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2013 · Synced Oct 20, 2026, 9:50 AM EDT
Completed Phase 1 Interventional

Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100

NCT01008527
View directory record Official record
Conditions
Melanoma
Interventions
CP 870,893, Peptides, Oncovir poly IC:LC
Drug · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 20, 2026, 9:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intrapartum Glycemic Control With Insulin Infusion Versus Rotating Fluids

NCT03912363
View directory record Official record
Conditions
Type II Diabetes Mellitus, Gestational Diabetes Mellitus
Interventions
Rotating fluids protocol, Insulin infusion protocol
Other
Lead sponsor
Geisinger Clinic
Other
Eligibility
14 Years to 50 Years · Female only
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
2
States / cities
Danville, Pennsylvania • Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 20, 2026, 9:50 AM EDT
Recruiting Phase 3 Interventional

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

NCT07466316
View directory record Official record
Conditions
Rhabdomyosarcoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Cyclophosphamide, Dactinomycin, Irinotecan Hydrochloride, Lumbar Puncture, Lymph Node Biopsy, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy, Resection, Survey Administration, Vincristine Sulfate, Vinorelbine Tartrate
Procedure · Drug · Biological + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 50 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
86
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 71 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 20, 2026, 9:50 AM EDT
Completed Phase 2 Interventional Results available

A Study of Flurpiridaz (18F) Injection for PET Imaging for Assessment of MPI Quality Using HPLC and SPE Manufacturing Processes

NCT04594941
View directory record Official record
Conditions
Coronary Artery Disease (CAD), Ischemic Heart Disease
Interventions
Flurpiridaz (18F) Injection
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
5
States / cities
Hialeah, Florida • Miami, Florida • North Miami Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 20, 2026, 9:50 AM EDT